Mode
Text Size
Log in / Sign up
Phase 4 N=20 Treatment

Treatment of Nicotine Dependence and Acute Depression

Major Depressive Disorder · Nicotine Dependence

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Hamilton Depression Scale Score — -.5322 percentage of change in depression — p=<.001

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
bupropion and smoking cessation behavioral intervention (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Stanford University
Primary completion
Sep 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Hamilton Depression Scale Score
-.5322 <.001 sig
PRIMARY
Cessation of Smoking
7
PRIMARY
Can Depression and Smoking Cessation be Treated Simultaneously
9

Summary

The purpose of this study is to assess the safety and feasibility of concurrent treatment of nicotine dependence (cigarette smoking) and acute depression. Participants who meet DSM-IV criteria for both nicotine dependence and acute major depression will be given pharmacological treatment for both disorders at the same time, along with a brief behavioral intervention for smoking cessation.

Eligibility Criteria

Inclusion Criteria

  • Age at least 18 at the beginning of the study
  • Smoking at least 10 cigarettes a day (1/2 pack)
  • Meets DSM-IV criteria for major depressive episode

Exclusion Criteria

  • Currently pregnant
  • Currently breastfeeding
  • Currently diagnosed with a seizure disorder, liver disease, kidney disease, congestive heart failure or diabetes mellitis
  • History of a seizure, seizure disorder, significant head trauma or central nervous system tumor
  • Family history of seizures
  • Currently using intravenous drugs
  • Currently using any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.) on a daily basis
  • Currently using any over-the-counter stimulants and anorectics (diet pills)
  • Currently on fluoxetine (Prozac), bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL) or any other antidepressants, monoamine oxidase inhibitors, antipsychotics, benzodiazepines, theophylline, systemic steroids or levodopa
  • Currently on NRT or bupropion (Zyban)
  • Current or past diagnosis of anorexia nervosa
  • Previous allergic response to fluoxetine, bupropion, or NRT
  • Previous failed quit attempt using NRT and bupropion in combination
  • Current suicidal ideation
  • Current or past psychosis, mania/hypomania, or any other Axis I or Axis II psychiatric diagnosis other than major depression and nicotine dependence
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00186446). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search